Bavarian Nordic named Tarja Stenvall—previously a Sanofi executive—as its next President and CEO, effective Oct. 15. Stenvall succeeds Paul Chaplin, who had led the Danish vaccine company for more than a decade. Stenvall’s appointment follows her role at Sanofi as SVP and Head of Global Franchise for Diabetes and Cardiovascular Diseases, where she led a roughly €10 billion franchise. Her earlier leadership experience spans Europe and Latin America, according to the company’s announcement. The management change comes as vaccine-focused companies continue to weigh manufacturing readiness, government contracting pipelines, and platform investment decisions. A new CEO can also shift portfolio emphasis—especially in smallpox, RSV-adjacent, and broader immunization strategies—where execution and partnerships drive outcomes. For investors and partners, the leadership handoff is a near-term signal for how Bavarian Nordic will allocate resources and governance as it navigates commercial and clinical priorities.